GHK-Cu

GHK-Cu is a copper-binding tripeptide (Gly-His-Lys) complexed with copper(II), researched for skin regeneration, collagen stimulation, wound healing, and broader anti-aging effects. It is one of the longest-studied peptides in cosmetic science, with both topical cosmetic and injectable research applications. The GHK tripeptide itself has a molecular weight of 340.4 Da; Peptigrity does not publish a single MW for the copper complex because sources conflict on it. GHK-Cu anchors Peptigrity's skin and anti-aging peptides category. Important regulatory update: Injectable GHK-Cu was removed from the FDA's Category 2 bulk substances list on April 22, 2026 and is slated for Pharmacy Compounding Advisory Committee (PCAC) consideration before the end of February 2027. Non-injectable GHK-Cu was separately removed from Category 1 in the same April 2026 action; the before-February-2027 PCAC consideration concerns the injectable form.

Source: GHK (glycyl-L-histidyl-L-lysine), copper-FREE tripeptide — compound identity, PubChem (NCBI), PubChem, 2026

What is GHK-Cu and how does the copper-tripeptide mechanism work?

GHK-Cu is the tripeptide Gly-His-Lys (GHK) complexed with copper(II), which dramatically increases the peptide's biological activity. The intact complex acts through multiple mechanisms: copper-dependent enzyme activation (lysyl oxidase for collagen crosslinking, superoxide dismutase for antioxidant defense), direct stimulation of dermal fibroblasts, anti-inflammatory effects, and gene expression modulation. GHK-Cu has been shown to alter the expression of a large fraction of tested human genes — in the Broad Institute Connectivity Map analyses summarized by Pickart and Margolina, 31.2% of human genes examined showed a ≥50% change in expression in response to GHK, reflecting broad biological effects. Endogenous GHK levels in plasma decline substantially with age — from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60 in the data summarized by Pickart.

Source: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data, Pickart L., Margolina A., Int J Mol Sci, 2018 · Evidence level: established cosmetic use with human topical studies; preclinical extensive (collagen, wound healing, gene expression); no human trials of injectable use

What does the research show for GHK-Cu?

Topical GHK-Cu has been used in cosmetic skincare for decades, and the human evidence sits on this side of the ledger: in the facial-cream data summarized in Pickart and Margolina's 2018 peer-reviewed review, 12 weeks of a GHK-Cu cream in 71 women with photoaged skin increased skin density and thickness, reduced laxity, and reduced fine lines and wrinkle depth. Most of these cosmetic studies were industry-run panels reported in reviews rather than standalone registered trials — real human data, but below drug-trial grade. Injectable and systemic GHK-Cu is preclinical only: injected GHK-Cu accelerated wound healing and collagen accumulation in animal models (rat wound and ligament-repair studies among them), but no human clinical trial of injectable GHK-Cu has been published as of August 2026 — every human dataset is topical/cosmetic. The compound has been one of the most-referenced ingredients in evidence-based cosmetic science. The GHK-Cu copper peptide collagen and skin science article covers the mechanism literature in depth, and the peptides for hair growth follicle research article covers the hair-specific data.

Sources: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data, Pickart L., Margolina A., Int J Mol Sci, 2018; In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds, — (optional, non-blocking: complete author list from the record), J Clin Invest, 1993 · Evidence level: Topical: established cosmetic use, human cosmetic studies; injectable: preclinical only

How does GHK-Cu compare to AHK-Cu and other cosmetic peptides?

GHK-Cu and AHK-Cu are the two main copper tripeptides in cosmetic and research use — GHK-Cu for general skin regeneration and collagen, AHK-Cu primarily for hair follicle stimulation. Different tripeptide sequences (Gly-His-Lys versus Ala-His-Lys) confer different tissue specificity.

What are the documented side effects of GHK-Cu?

Topical GHK-Cu has an extensive cosmetic safety record with rare reports of contact dermatitis as the primary concern. Injectable use side effects in available research and community-reported use are mild — injection-site reactions, occasional transient flushing. The copper content raises theoretical concerns about copper accumulation with sustained high-dose use, though clinically meaningful copper toxicity has not been reported at researched doses.

Evidence level: extensive cosmetic safety; injectable research safety; long-term high-dose unestablished

What is the regulatory status of GHK-Cu?

Topical GHK-Cu is widely incorporated into cosmetic skincare products and is not subject to specific therapeutic regulation in cosmetic-grade use. Injectable GHK-Cu is not approved for any therapeutic indication. On April 15, 2026 (effective within seven calendar days — April 22, 2026), the FDA removed GHK-Cu for injectable routes of administration from Category 2 of the 503A bulk-substances lists, one of twelve peptides removed because — in FDA's words — their nominations were withdrawn by the nominators; GHK-Cu for non-injectable routes was separately removed from Category 1 in the same action. Removal is not approval and does not authorize compounding: GHK-Cu now sits in FDA's "nominated but withdrawn" table, which flags that compounded injectable GHK-Cu "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities." The FDA has stated it will convene the Pharmacy Compounding Advisory Committee before the end of February 2027 to consider GHK-Cu (injectable routes of administration), alongside LL-37, dihexa acetate, PEG-MGF, and melanotan II. Current status in FDA peptide regulation 2025–2026 timeline.

Sources: FDA Announces Removal of 12 Peptides from Category 2 (nominations withdrawn by the nominators) and Schedules PCAC Meetings, Orrick (legal analysis of the FDA notice), via Orrick Insights; FDA 503A bulk drug substances (Category 1/2) page; FDA Pharmacy Compounding Advisory Committee meeting scheduled before end of February 2027 — 503A bulks consideration (LL-37, dihexa acetate, injectable GHK-Cu, PEG-MGF, melanotan II), FDA

Why does GHK-Cu vendor verification matter?

GHK-Cu is widely sold across cosmetic, supplement, and research-grade supply chains with substantial quality variance — and the copper-complexed form versus free GHK peptide are pharmacologically distinct. Some vendors sell free GHK labeled as GHK-Cu (mislabeling) or use suboptimal copper-to-peptide ratios. Compare vendors against the independent GHK-Cu lab tests on file, and see the where to buy GHK-Cu purity and identity checks guide for the full 7-check framework. Independent HPLC and copper content verification are the meaningful quality signals. Guidance in how-to-test-peptides hub.

How does Peptigrity verify GHK-Cu vendors?

Peptigrity collects independent third-party Certificates of Analysis for GHK-Cu from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does GHK-Cu do?

GHK-Cu stimulates collagen production, supports skin regeneration and wound healing, and produces broad anti-aging effects on skin through multiple molecular mechanisms. Topical use has extensive cosmetic evidence; injectable use is researched but lacks Phase 2/3 RCT-grade human data.

Is GHK-Cu legal to purchase?

Topical GHK-Cu is widely available in cosmetic skincare products. Injectable GHK-Cu is legal to purchase as a research chemical for laboratory use in most jurisdictions but is not approved for human consumption. The April 22, 2026 Category 2 removal reflects withdrawn nominations, not a safety clearance — it does not itself authorize compounding; PCAC consideration of the injectable form is slated before the end of February 2027. Country breakdown in peptide legal status guide.

When will the FDA decide on injectable GHK-Cu?

No decision date exists yet. The FDA has said it will convene its Pharmacy Compounding Advisory Committee before the end of February 2027 to consider GHK-Cu for injectable routes of administration. PCAC votes are advisory — at the July 2026 meeting on other peptides, FDA staff opposed inclusion and no recommendation has been finalized into rulemaking — so a committee discussion is not an approval and compounding remains unauthorized in the meantime.

Source: FDA Pharmacy Compounding Advisory Committee meeting scheduled before end of February 2027 — 503A bulks consideration (LL-37, dihexa acetate, injectable GHK-Cu, PEG-MGF, melanotan II), FDA

How can I verify a GHK-Cu vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation and copper content verification. The copper-complexed form is what produces the biological activity; free GHK without copper has much weaker effects. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a GHK-Cu dose?

No. Peptigrity is an independent review platform, not a medical authority. Topical cosmetic dosing follows product instructions; injectable research-use dosing varies. Anyone considering injectable use should consult a licensed physician. For reconstitution math on research-grade material, the GHK-Cu calculator handles vial size, bacteriostatic-water volume, and concentration.

Is GHK-Cu safe long-term?

Topical GHK-Cu has an extensive cosmetic safety record. Injectable long-term safety at sustained research-use dosing is less characterized than cosmetic use, with theoretical concerns about copper accumulation but no clinically reported toxicity at researched doses. Anyone considering sustained injectable use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Research-grade injectable GHK-Cu sold for laboratory use is not an FDA-approved product; topical GHK-Cu is sold as a cosmetic ingredient. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.